Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 189-196

  Dai, Mei ^a   Xu, Xu ^a   Song, Jia ^a   Fu, ShaoZhi ^a   Gou, MaLing ^a   Luo, Feng ^a   Qian, ZhiYong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Camptothecin; Colorectal cancer; Colorectal peritoneal carcinomatosis; Microsphere; Poly ( caprolactone) poly (ethyleneglycol) poly ( caprolactone) (PCL PEG PCL, PCEC)

Indexed keywords

CAMPTOTHECIN; LEUKOSIALIN; MICROSPHERE; OIL; POLYCAPROLACTONE MACROGOL POLYCAPROLACTONE MICROSPHERE; SOLVENT; UNCLASSIFIED DRUG; WATER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; COLORECTAL CANCER; COLORECTAL PERITONEAL CARCINOMATOSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG RELEASE; EMULSION; ENCAPSULATION; EVAPORATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEAL CAVITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DRUG CARRIERS; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; PERITONEAL NEOPLASMS; POLYMERS;

MUS;

EID: 80054008615     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.007     Document Type: Article

References (36)

1. Wang Y., Gong C., Yang L., Wu Q., Shi S., Shi H., Qian Z., Wei Y. 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer 2010, 10:402.
2. Chau I., Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treatment Reviews 2002, 28:223-236.
3. Lu Z., Wang J., Wientjes M.G., Au J.L.S. Intraperitoneal therapy for peritoneal cancer. Future Oncology 2010, 6:1625-1641.
4. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis J., Rubin S., Curtin J., Barakat R., Phillips M. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. Journal of Clinical Oncology 1992, 10:1485.
5. Elias D.M., Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surgical Oncology Clinics of North America 2003, 12:755.
6. Wenzel L.B., Huang H.Q., Armstrong D.K., Walker J.L., Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007, 25:437.
7. Min K.H., Park K., Kim Y.S., Bae S.M., Lee S., Jo H.G., Park R.W., Kim I.S., Jeong S.Y., Kim K. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. Journal of Controlled Release 2008, 127:208-218.
8. Lorence A., Nessler C.L. Camptothecin, over four decades of surprising findings. Phytochemistry 2004, 65:2735-2749.
9. Zhu A., Yuan L., Jin W., Dai S., Wang Q., Xue Z., Qin A. Polysaccharide surface modified Fe3O4 nanoparticles for camptothecin loading and release. Acta Biomater 2009, 5:1489-1498.
10. Tong W., Wang L., D'Souza M.J. Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Development and Industrial Pharmacy 2003, 29:745-756.
11. Ertl B., Platzer P., Wirth M., Gabor F. Poly(-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. Journal of Controlled Release 1999, 61:305-317.
12. Schneider T., Zhao H., Jackson J.K., Chapman G.H., Dykes J., Häfeli U.O. Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin-loaded polymer microspheres. Journal of Pharmaceutical Sciences 2008, 97:4943-4954.
13. Koshkina N.V., Gilbert B.E., Waldrep J.C., Seryshev A., Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemotherapy and Pharmacology 1999, 44:187-192.
14. Watanabe M., Kawano K., Toma K., Hattori Y., Maitani Y. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. Journal of Controlled Release 2008, 127:231-238.
15. Ngawhirunpat T., Wonglertnirant N., Opanasopit P., Ruktanonchai U., Yoksan R., Wasanasuk K., Chirachanchai S. Incorporation methods for cholic acid chitosan-g-mPEG self-assembly micellar system containing camptothecin. Colloids and Surfaces B: Biointerfaces 2009, 74:253-259.
16. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., Maitani Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. Journal of Controlled Release 2006, 112:329-332.
17. Cortesi R., Esposito E., Maietti A., Menegatti E., Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. International Journal of Pharmaceutics 1997, 159:95-103.
18. Tsai M., Lu Z., Wang J., Yeh T.K., Wientjes M.G., Au J.L.S. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharmaceutical Research 2007, 24:1691-1701.
19. Dora C.L., Alvarez-Silva M., Trentin A.G., de Faria T.J., Fernandes D., da Costa R., Stimamiglio M., Lemos-Senna E. Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells. Journal of Pharmacy & Pharmaceutical Sciences 2006, 9:22-31.
20. McCarron P.A., Marouf W.M., Quinn D.J., Fay F., Burden R.E., Olwill S.A., Scott C.J. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjugate Chemistry 2008, 19:1561-1569.
21. Kumar V., Kang J., Hohl R.J. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying. Pharmaceutical Development and Technology 2001, 6:459-467.
22. Liu X., Zhou S., Li X., Chen X., Zhao X., Qian Z., Zhou L., Li Z., Wang Y., Zhong Q. Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. Journal of Experimental & Clinical Cancer Research 2010, 29:1-9.
23. Zhou L., Li X., Chen X., Li Z., Liu X., Zhou S., Zhong Q., Yi T., Wei Y., Zhao X. In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer. Cancer Letters 2010, 297:56-64.
24. Cirpanli Y., Bilensoy E., Lale Dogan A., Calis S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. European Journal of Pharmaceutics and Biopharmaceutics 2009, 73:82-89.
25. Swaminathan S., Pastero L., Serpe L., Trotta F., Vavia P., Aquilano D., Trotta M., Zara G.P., Cavalli R. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. European Journal of Pharmaceutics and Biopharmaceutics 2010, 74:193-201.
26. Wei X.W., Gong C.Y., Gou M.L., Fu S.Z., Guo Q.F., Shi S., Luo F., Guo G., Qiu L.Y., Qian Z.Y. Biodegradable poly (-caprolactone)-poly (ethylene glycol) copolymers as drug delivery system. International Journal of Pharmaceutics 2009, 381:1-18.
27. Jeong Y.I., Kang M.K., Sun H.S., Kang S.S., Kim H.W., Moon K.S., Lee K.J., Kim S.H., Jung S. All-trans-retinoic acid release from core-shell type nanoparticles of poly (ε -caprolactone)/poly (ethylene glycol) diblock copolymer. International Journal of Pharmaceutics 2004, 273:95-107.
28. Letchford K., Liggins R., Wasan K.M., Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly (ethylene glycol)-block-poly (caprolactone) nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2009, 71:196-206.
29. Forrest M.L., Won C.Y., Malick A.W., Kwon G.S. In vitro release of the mTOR inhibitor rapamycin from poly (ethylene glycol)-b-poly ([epsilon]-caprolactone) micelles. Journal of Controlled Release 2006, 110:370-377.
30. Jette K.K., Law D., Schmitt E.A., Kwon G.S. Preparation and drug loading of poly (ethylene glycol)-block-poly (ε -caprolactone) micelles through the evaporation of a cosolvent azeotrope. Pharmaceutical Research 2004, 21:1184-1191.
31. Jia W.J., Gu Y.C., Gou M.L., Dai M., Li X.Y., Kan B., Yang J.L., Song Q.F., Wei Y.Q., Qian Z.Y. Preparation of biodegradable polycaprolactone/poly (ethylene glycol)/polycaprolactone (PCEC) nanoparticles. Drug Delivery 2008, 15:409-416.
32. Gou M.L., Dai M., Li X.Y., Wang X.H., Gong C.Y., Xie Y., Wang K., Zhao X., Qian Z.Y., Wei Y.Q. Preparation and characterization of honokiol nanoparticles. Journal of Materials Science: Materials in Medicine 2008, 19:2605-2608.
33. Gou M.L., Dai M., Li X.Y., Yang L., Huang M.J., Wang Y.S., Kan B., Lu Y., Wei Y.Q., Qian Z.Y. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids and Surfaces B: Biointerfaces 2008, 64:135-139.
34. Gou M., Dai M., Gu Y., Li X., Wen Y., Yang L., Wang K., Wei Y., Qian Z. Basic fibroblast growth factor loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: preparation, in vitro release and immunogenicity study. Journal of Nanoscience and Nanotechnology 2008, 8:2357-2361.
35. Huang M.J., Gou M.L., Qian Z.Y., Dai M., Li X.Y., Cao M., Wang K., Zhao J., Yang J.L., Lu Y. One-step preparation of poly (ε -caprolactone)-poly (ethylene glycol)-poly (ε -caprolactone) nanoparticles for plasmid DNA delivery. Journal of Biomedical Materials Research Part A 2008, 86:979-986.
36. Clements M.K., Jones C.B., Cumming M., Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemotherapy and Pharmacology 1999, 44:411-416.